Navigation Links
Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Fourth Quarter and Full Year Financial Results
Date:2/23/2010

of-concept for two of our four clinical programs, with positive results in Phase 2 clinical trials for both LX1031 in IBS and LX4211 in type 2 diabetes," said Dr. Arthur T. Sands, president and chief executive officer of Lexicon.  "We look forward to reporting Phase 2 clinical results from our next two programs, LX2931 for rheumatoid arthritis and LX1032 for carcinoid syndrome."

Key Developments of 2009

  • Lexicon reported positive results from the Phase 2a clinical trial of its drug candidate for non-constipating irritable bowel syndrome (IBS), LX1031, an inhibitor of tryptophan hydroxylase that acts locally to reduce serotonin synthesis in the gastrointestinal tract.  Top-line data demonstrated that t
    '/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Lexicon Announces Proposed Offering of 27,500,000 Shares of Common Stock
2. Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
3. Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2009 Financial Results on July 28, 2009
4. Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
5. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
6. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
7. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2009 Financial Results on April 28, 2009
8. Lexicon Pharmaceuticals 2008 Annual Report to Stockholders Available Online
9. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
10. Lexicon to Report Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008
11. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... China Biologic Products, Inc. (NASDAQ: CBPO, ... integrated plasma-based biopharmaceutical company in China ... Shandong Taibang Biological Products Co. Ltd., has received ... Food and Drug Administration (the "CFDA") for its ... in the Company,s public filings, the CFDA inspected ...
(Date:12/24/2014)... Sigma-Aldrich Corporation (NASDAQ: SIAL ... the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act) in ... 2014, thereby completing the U.S. HSR Act antitrust ... the Company by Merck KGaA, Darmstadt, Germany.  ... to closing the transaction, which remains subject to ...
(Date:12/22/2014)... Malvern, PA & Brussels (PRWEB) December 22, 2014 ... Education (CfPIE), the global leader of technical training ... Society for Clinical Data Management (SCDM) to ... training and certification programs —providing access to the ... The partnership extends SCDM members with 10% off when ...
(Date:12/22/2014)... N.C. , Dec. 22, 2014  Alternative ... announced that it has signed a letter of ... that has developed and patented a nanotechnology-based development ... diagnostics products that enable rapid on-site collection and ... use/abuse and health issues in an immediate, non-invasive ...
Breaking Biology Technology:China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3ALNE Announces Intention To Acquire BioTechPharma 2
... N.J., Feb. 5 Covance Inc. (NYSE:,CVD) today announced ... Biotechnology and Medical Device Conference on February 6th,at 9:20 ... the presentation at, http://www.covance.com . In order to register ... early., Covance, with headquarters in Princeton, New Jersey, ...
... 5 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq:,ONTY) (TSX: ONY), ... therapeutic products for the treatment of cancer, today,announced ... http://www.oncothyreon.com ., "We are excited about ... updated website, which provides additional information about our,product ...
... (Nasdaq: KERX ) today announced that Michael S. Weiss, ... the following,upcoming Investor Conferences:, Thursday, February 7th, 2008 - ... & Medical,Device Conference, Grand Hyatt Hotel ... 12:30 PM ET: BIO CEO & Investor Conference ...
Cached Biology Technology:Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations 2
(Date:12/10/2014)... , Dec. 9, 2014  Wake Forest Baptist Medical Center ... for its School of Medicine. Funding for this $50 ... campaign that will be publicly launched next summer. ... in the former 60 series R.J. Reynolds Tobacco Company ... Construction will begin immediately with plans to be ready ...
(Date:12/5/2014)... MOUNTAIN VIEW, Calif. , Dec. 4, 2014 ... and safety has boosted investments in new testing ... products has also given rise to a range ... driven by the requirements of Generation Y, which ... digital technologies. As a result, product development strategies ...
(Date:12/3/2014)... , Dec. 2, 2014 As part of ... Inception Technologies is pleased to announce the release of ... customers to collect the workforce data that they need. ... have been left by existing readers. Many such devices ... connectivity and modern technology. Older models force users to ...
Breaking Biology News(10 mins):Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Inception Technologies to Release New Biometric Reader 2
... have been identified as highly efficient generators of electricity. , ... high concentrations in the stratosphere orbiting the earth with the ... biofilm that has been engineered by a team of scientists ... from the Wear Estuary, Country Durham, UK, the team tested ...
... N.M Sandia National Laboratories researchers, using off-the-shelf ... on ways to improve amputees, control over prosthetics ... Organic materials chemist Shawn Dirk, robotics engineer Steve ... The goal is improved prosthetics with flexible nerve-to-nerve ...
... Researchers at The Pennsylvania State University College of ... integrity of the opioid growth factor receptor (OGFr), which ... on cell proliferation, is a key to understanding the ... of human ovarian cancer cells that were molecularly engineered ...
Cached Biology News:Superbugs from space offer new source of power 2Sandia seeks better neural control of prosthetics for amputees 2Sandia seeks better neural control of prosthetics for amputees 3Sandia seeks better neural control of prosthetics for amputees 4Sandia seeks better neural control of prosthetics for amputees 5A breakthrough in understanding the biology and treatment of ovarian cancer 2A breakthrough in understanding the biology and treatment of ovarian cancer 3
... to Cytokeratin 5 / 6 Cytokeratin ... weight, basic type of cytokeratin expressed in ... layers of stratified epithelia as well as ... cells and mesothelioma. Cytokeratin 6 (56 kD) ...
Aldolase A (N-15)...
... Y2 Receptor antiserum This NPY Y2 ... level and is currently being characerized in brain. ... and mouse and appears to work better on ... rat. For full characterizarion in dorsal root ganglion ...
Black Polypropylene 384 Round Well Plate 70/Box...
Biology Products: